ARTICLE | Clinical News
Enrollment completed in first palonosetron Phase III
October 3, 2001 7:00 AM UTC
MGI Pharma (MOGN) partner Helsinn (Lugano, Switzerland) completed enrollment in the first Phase III trial comparing Helsinn's intravenous palonosetron, a 5-HT3 antagonist, to marketed 5-HT3 antagonist...